A number of research firms have changed their ratings and price targets for Eli Lilly and Company (NYSE: LLY):
- 7/15/2026 – Eli Lilly and Company had its price target raised by Citigroup Inc. from $1,500.00 to $1,600.00. They now have a “buy” rating on the stock.
- 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
- 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
- 7/13/2026 – Eli Lilly and Company had its price target raised by UBS Group AG from $1,250.00 to $1,425.00. They now have a “buy” rating on the stock.
- 7/13/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,235.00 to $1,273.00. They now have a “buy” rating on the stock.
- 7/10/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,251.00 to $1,334.00. They now have a “buy” rating on the stock.
- 7/9/2026 – Eli Lilly and Company was given a new $1,370.00 price target by UBS Group AG.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,281.00 to $1,370.00. They now have a “buy” rating on the stock.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,344.00 to $1,347.00. They now have an “overweight” rating on the stock.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,250.00 to $1,500.00. They now have an “outperform” rating on the stock.
- 7/7/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,300.00 to $1,400.00. They now have an “overweight” rating on the stock.
- 7/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,230.00 to $1,350.00. They now have an “overweight” rating on the stock.
- 7/1/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
- 6/25/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,119.00 to $1,232.00. They now have an “outperform” rating on the stock.
- 6/22/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 6/22/2026 – Eli Lilly and Company had its price target raised by Berenberg Bank from $1,050.00 to $1,135.00. They now have a “hold” rating on the stock.
- 6/15/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
- 6/9/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,330.00 to $1,350.00. They now have a “buy” rating on the stock.
- 6/8/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein.
- 6/5/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley.
- 5/26/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,133.00 to $1,251.00. They now have a “buy” rating on the stock.
- 5/26/2026 – Eli Lilly and Company was given a new $1,119.00 price target by Leerink Partners.
- 5/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $1,283.00 price target on the stock.
- 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,350.00 price target on the stock.
- 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada.
- 5/21/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,300.00 to $1,330.00.
- 5/19/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
See Also
- Five stocks we like better than Eli Lilly and Company
- Cintas Keeps Beating Expectations—And the Story Isn’t Over
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
